申请人:ZENECA LIMITED
公开号:US20030119830A1
公开(公告)日:2003-06-26
The invention concerns the use of a compound of formula (I), in which Z, X, T, A, R
1
, R
2
, p and q have any of the meanings defined herein, and their pharmaceutically acceptable salts or in vivo hydrolysable esters, in the treatment of a disease or condition mediated by monocyte chemoattractant protein-1 (MCP-1). Certain of the components of formula (I) are novel and are provided, together with pharmaceutical compositions thereof, as further features of the invention.
本发明涉及使用式(I)的化合物,其中Z,X,T,A,R1,R2,p和q具有本文所定义的任何含义,以及其药学上可接受的盐或体内水解酯,在治疗由单核细胞趋化蛋白-1(MCP-1)介导的疾病或状况中的应用。式(I)的某些组分是新颖的,并且作为本发明的进一步特征提供其制药组合物。